Loading organizations...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) operates as a primary component of the National Institutes of Health, dedicated to advancing public health. The Institute conducts and supports extensive medical research across a broad spectrum of chronic diseases, including diabetes, various endocrine and metabolic conditions, digestive disorders, nutritional challenges, obesity, and diseases affecting the kidney, urologic, and hematologic systems. It also provides research training and disseminates science-based information to improve health outcomes.
NIDDK was formally established on August 15, 1950, when President Harry S. Truman signed the Omnibus Medical Research Act into law. This legislative act initially created the National Institute of Arthritis and Metabolic Diseases (NIAMD), which expanded upon existing research capabilities to address a wider range of clinical investigations in significant disease areas. The foresight behind its creation was to centralize and enhance federal efforts in understanding and combating these prevalent health issues.
The Institute serves a diverse group, including scientific researchers, medical professionals, and ultimately, patients and their families. NIDDK's overarching mission is to improve the health and quality of life for all individuals by aggressively pursuing medical breakthroughs and ensuring that evidence-based health information reaches those who can benefit most. It continuously works towards fostering a robust pipeline of new scientific talent to address future health challenges.
National Institute of Diabetes and Digestive and Kidney Diseases has 4 tracked investments across 3 companies. The latest tracked deal is $1.7M Grant in Zylö Therapeutics in July 2021.
